20 May 2009 - Operon Biotechnologies has announced it will work with Eurofins MWG and Eurofins Medigenomix to create custom oligonucleotides.
The combined network takes in about USD50M (GBP32M) in revenue and has high-throughput production facilities in all major markets (North America, Europe and Asia).
